A Phase I trial of talazoparib in patients with advanced hematologic malignancies.

Ajay K Gopal Rakesh Popat Ryan J MattisonTobias MenneAdrian BloorTerry GaymesAsim Khwaja Mark B JuckettYing ChenMatthew J CotterGhulam J Mufti

Published in: International journal of hematologic oncology (2021)

Talazoparib is relatively well tolerated in hematologic malignancies, with a similar MTD as in solid tumors, and shows preliminary anti leukemic activity.Clinical trial registration: NCT01399840 (ClinicalTrials.gov).

Keyphrases

clinical trial
phase ii

phase iii
study protocol

open label
acute myeloid leukemia

double blind